Effect of Renal Impairment on the Pharmacokinetics and Safety of Dorzagliatin, a Novel Dual-acting Glucokinase Activator.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and translational science"
DOI: 10.1111/cts.13174
Abstract: Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI)… read more here.
Keywords: dorzagliatin novel; glucokinase; effect renal; glucokinase activator ... See more keywords